Amyloid-β oligomers relate to cognitive decline in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 35-43

  Jongbloed, Wesley ^a   Bruggink, Kim A ^b   Kester, Maartje I ^a   Visser, Pieter Jelle ^a,c   Scheltens, Philip ^a   Blankenstein, Marinus A ^a   Verbeek, Marcel M ^b   Teunissen, Charlotte E ^a   Veerhuis, Robert ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; amyloid peptides; biological markers; cerebrospinal fluid; cognition; dementia; disease progression; mild cognitive impairment

Indexed keywords

AMYLOID BETA OLIGOMER; AMYLOID BETA PROTEIN; OLIGOMER; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; COGNITION DISORDERS; COMPLICATION; MENTAL HEALTH; MIDDLE AGED; STATISTICS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PEPTIDE FRAGMENTS; STATISTICS AS TOPIC;

EID: 84924116461     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142136     Document Type: Article

References (41)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
2. Eikelenboom P, Veerhuis R, Van Exel E, Hoozemans JJM, Rozemuller AJM, Van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: Neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8, 142-150.
3. Sakono M, Zako T (2010) Amyloid oligomers: Formation and toxicity of Abeta oligomers. FEBS J 277, 1348-1358.
4. Williams TL, Serpell LC (2011) Membrane and surface interactions of the Alzheimer's Aβ peptide: Insights into the mechanism of cytotoxicity. FEBS J 278, 3905-3917.
5. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453.
6. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819-5824.
7. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
8. Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG (2013) Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducingAβdeposition and tau pathology in 3xTg-AD mice. J Neurochem 126, 473-482.
9. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, Nolte MW, Perez-Cruz C, Van Der Auwera I, Van Leuven F, Van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U (2010) Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 30, 10369-10379.
10. Kasai T, Tokuda T, Taylor M, Kondo M, Mann DMA, Foulds PG, Nakagawa M, Allsop D (2013) Correlation of Aβ oligomer levels in matched cerebrospinal fluid and serum samples. Neurosci Lett 551, 17-22.
11. Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K (2013) Evaluating amyloid-&brta; oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One 8, e66381.
12. Bruggink KA, Jongbloed W, Biemans EALM, Veerhuis R, Claassen JAHR, Kuiperij HB, VerbeekMM (2013) Amyloid-&brta; oligomer detection by enzyme-linked immunosorbent assay in cerebrospinal fluid and brain tissue. Anal Biochem 433, 112-120.
13. Funke SA, Wang L, Birkmann E, Willbold D (2010) Singleparticle detection system for Aβ aggregates: Adaptation of surface-fluorescence intensity distribution analysis to laser scanning microscopy. Rejuvenation Res 13, 206-209.
14. Wang-Dietrich L, Funke SA, Kühbach K, Wang K, Besmehn A, Willbold S, Cinar Y, Bannach O, Birkmann E, Willbold D (2013) The amyloid-&brta; oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 34, 985-994.
15. Rushworth JV, Ahmed A, Griffiths HH, Pollock NM, Hooper NM, Millner PA (2014) A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloidbeta oligomers. Biosens Bioelectron 56, 83-90.
16. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Böhm G (2007) Detection of amyloid-beta oligomers in human cerebrospinal fluid by flowcytometry and fluorescence resonance energy transfer. J Alzheimers Dis 11, 117-125.
17. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) High-molecularweight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24, 2716-2726.
18. Santos AN, Ewers M, Minthon L, Simm A, Silber R-E, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-&brta; oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29, 171-176.
19. Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A (2014) A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci 34, 2884-2897.
20. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. (2013) A Luminex assay detects amyloid aβ oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8, e67898.
21. Kester MI, Scheffer PG, Koel-Simmelink MJ, TwaalfhovenH, Verwey NA, Veerhuis R, Twisk JW, Bouwman FH, Blankenstein MA, Scheltens P, Teunissen C, Van Der FlierWM (2012) Serial CSF sampling in Alzheimer's disease: Specific versus non-specific markers. Neurobiol Aging 33, 1591-1598.
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
24. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
25. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
26. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
27. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, LeeVMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
28. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, Van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922.
29. Verwey NA, Veerhuis R, Twaalfhoven HAM, Wouters D, Hoozemans JJM, Bollen YJM, Killestein J, Bibl M, Wiltfang J, Hack CE, Scheltens P, Blankenstein MA (2009) Quantification of amyloid-beta 40 in cerebrospinal fluid. J Immunol Methods 348, 57-66.
30. Rahimi F, Maiti P, Bitan G (2009) Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. J Vis Exp 23, 1071.
31. Bitan G (2006) Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. Methods Enzymol 413, 217-236.
32. Verwey NA, Hoozemans JJM, Korth C, Van Royen MR, Prikulis I, Wouters D, Twaalfhoven HAM, Van Haastert ES, Schenk D, Scheltens P, Rozemuller AJM, Blankenstein MA, Veerhuis R (2013) Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide. Amyloid 20, 179-187.
33. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
34. Resende R, Ferreiro E, Pereira C, Resende De Oliveira C (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155, 725-737.
35. Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid-&brta;oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398.
36. Holtzman DM (2011) CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging 32 (Suppl 1), S4-S9.
37. Bruggink KA, Müller M, Kuiperij HB, Verbeek MM (2012) Methods for analysis of amyloid-&brta; aggregates. J Alzheimers Dis 28, 735-758.
38. Klement K, Wieligmann K, Meinhardt J, Hortschansky P, Richter W, Fändrich M (2007) Effect of different salt ions on the propensity of aggregation and on the structure of Alzheimer's abeta (1-40) amyloid fibrils. J Mol Biol 373, 1321-1333.
39. Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26, 6011-6018.
40. Ma Q-L, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089.
41. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, BlennowK, AsheKH (2013) Correlation of specific amyloid-&brta; oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol 70, 1-6.